Fig. 4: PK and tissue distribution of POEM/siRNA NPs.
a Ex vivo imaging and quantified radiant efficiency of KPC-C2 subcutaneous tumor and major organs (H heart, Li liver, S spleen, Lu lung, K kidney, T tumor) at 24 h following intravenous administration of free siSPB9-cy5.5 or various POEM/siSPB9-cy5.5 NPs. n = 3 independent samples. b Ex vivo imaging and quantified radiant efficiency of KPC-C2 orthotopic pancreatic tumor and major organs at 24 h following intravenous administration of free siSPB9-cy5.5 or POEM/siSPB9-cy5.5 NPs at a ratio of 50/5/1. n = 3 independent samples. c Percentage of injected dose and tissue concentration of siSPB9 in different organs following i.v. injection of free siSPB9 or POEM/siSPB9 at a dose of 1 mg/kg for siRNA. n = 3 independent samples. d Plasma concentrations of siSPB9 over time after i.v. injection of siSPB9 or POEM/siSPB9 at a dose of 1 mg/kg for siRNA. n = 3 independent samples. e Pharmacokinetic parameters of siSPB9 were analyzed by a one-compartmental model. t1/2 half-life, AUC∞ the area under the plasma concentration versus time curve, AUMC∞ the area under the plasma concentration versus the first moment curve (AUMC), CL clearance, Vd volume of distribution. Data are presented as mean ± s.e.m. in (a–d). Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test for comparison in (a–c). Source data are provided as a Source Data file.
